VOLUME 60   1999   SUPPLEMENT 3

Articles

3 Outcome in Schizophrenia: Beyond Symptom Reduction. Herbert Y. Meltzer, M.D.
[Abstract] [PDF]

9 Methods of Cost-Effectiveness Analysis in the Evaluation of New Antipsychotics: Implications for Schizophrenia Treatment. Peter J. Neumann, Sc.D.
[Abstract] [PDF]

16 Mental Health Care From the Public Perspective: The Texas Medication Algorithm Project. Steven P. Shon, M.D.; M. Lynn Crismon, Pharm.D.; Marcia G. Toprac, Ph.D.; Madhukar Trivedi, M.D.; Alexander L. Miller, M.D.; Trisha Suppes, M.D., Ph.D.; and A. John Rush, M.D.
[Abstract] [PDF]

22 Cost-Utility Analysis in Schizophrenia. A. George Awad, M.D., Ph.D., and Lakshmi P. Voruganti, M.D., M.Sc.
[Abstract] [PDF]

29 The Wisconsin Quality of Life Index: A Multidimensional Model for Measuring Quality of Life. Ronald Diamond, M.D., and Marion Becker, Ph.D.
[Abstract] [PDF]

32 Perspective and the Measurement of Costs and Benefits for Cost-Effectiveness Analysis in Schizophrenia. David Meltzer, M.D., Ph.D.
[Abstract] [PDF]

38 What About the Patient? Daniel E. Weisburd
[Abstract] [PDF]

42 The Risperidone Outcomes Study of Effectiveness (ROSE): A Model for Evaluating Treatment Strategies in Typical Psychiatric Practice. Ramy Mahmoud, M.D.; Luella Engelhart, M.A.; Dan Ollendorf, M.P.H.; and Gerry Oster, Ph.D.
[Abstract] [PDF]

49 Cost of Treating Mental Illness From a Managed Care Perspective. John P. Docherty, M.D.
[Abstract] [PDF]

54 Panel on Cost-Effectiveness in Health and Medicine Recommendations: Identifying Costs. Willard G. Manning, Jr., Ph.D.
[Abstract] [PDF]

59 Concluding Discussion.
[PDF]